Pentostalin: Uses, Dosage, Side Effects, and More

Pentostalin, also known as Deoxycoformycin or Nipent®, is a chemotherapeutic drug primarily used in the treatment of hairy cell leukemia, a rare type of chronic leukemia. This comprehensive guide will explore the various aspects of Pentostalin, including its therapeutic uses, dosage and administration, side effects and adverse reactions, drug interactions, contraindications and precautions, pharmacokinetics, clinical trials and research, regulatory status, patient information, handling and storage, and historical and future perspectives.

1. Introduction to Pentostalin

Pentostalin is an antineoplastic and antimetabolite drug primarily used in the treatment of hairy cell leukemia, a rare type of chronic leukemia characterized by the presence of abnormal B-lymphocytes called hairy cells. It is a purine analogue that inhibits the enzyme adenosine deaminase, resulting in the accumulation of deoxyadenosine triphosphate (dATP) and the subsequent inhibition of DNA synthesis and cell division.

Source: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

2. Chemical Composition and Structure

Pentostalin, also known as Deoxycoformycin, has a molecular formula of C ₁₁H ₁₆N ₄O ₄. It is a purine analogue and a structural derivative of adenosine, with a modified ribose ring and an additional oxo group at the C-1 position of the purine ring. This structural modification allows Pentostalin to inhibit the enzyme adenosine deaminase, thereby exerting its antineoplastic effects.

Source: PubChem: Pentostatin

3. Mechanism of Action

Pentostalin is an antimetabolite and a purine analogue that exhibits its antineoplastic activities by inhibiting the enzyme adenosine deaminase (ADA). By inhibiting ADA, Pentostalin causes an accumulation of deoxyadenosine triphosphate (dATP) within cells, which subsequently inhibits DNA synthesis and cell division. This mechanism of action makes Pentostalin particularly effective against rapidly dividing cells, such as those found in certain types of leukemia and lymphomas.

Source: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

4. Therapeutic Uses

The primary therapeutic use of Pentostalin is in the treatment of hairy cell leukemia, a rare type of chronic leukemia characterized by the presence of abnormal B-lymphocytes called hairy cells. Pentostalin is considered the standard treatment for hairy cell leukemia and has been shown to induce complete or partial remission in a significant number of patients.

Additionally, Pentostalin has been used in the treatment of T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive form of mature T-cell leukemia. It has also been explored for potential use in other types of leukemias, such as acute nonlymphocytic leukemia, although its efficacy in these conditions is less well-established.

Source: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

5. Brand Names and Manufacturers

The most well-known brand name for Pentostalin is Nipent®, which is manufactured by SuperGen, Inc. (now part of Avecia Pharmaceuticals). However, other brand names for Pentostalin may exist in different regions or countries.

Source: Drugs.com: Nipent (Pentostatin) Drug Information

6. Dosage and Administration

Pentostalin is available as a lyophilized powder for intravenous administration. It is supplied in single-dose vials containing Pentostalin as a sterile, apyrogenic, lyophilized powder for reconstitution.

The recommended dosage of Pentostalin for the treatment of hairy cell leukemia is 4 mg/m² administered as an intravenous infusion every 2 weeks. The dosage may be adjusted based on the patient’s response and tolerability.

Source: FDA: Nipent (Pentostatin) Prescribing Information

7. Side Effects and Adverse Reactions

Pentostalin can cause various side effects, both common and less common. Some of the more common side effects include:

• Back pain
• Bloating or gas
• Constipation
• Dry skin
• General discomfort
• Itching
• Joint pain
• Weakness

Less common side effects may include fever, chills, nausea, vomiting, diarrhea, and various hematologic abnormalities.

Source: Drugs.com: Pentostalin Side Effects

8. Interactions with Other Drugs

Pentostalin may interact with other drugs, potentially affecting its efficacy or safety. Some known drug interactions include:

• Allopurinol: May increase the risk of Pentostalin-related toxicity
• Antiviral drugs (e.g., didanosine, stavudine): May increase the risk of Pentostalin-related toxicity
• Immunosuppressive agents (e.g., cyclosporine, tacrolimus): May increase the risk of Pentostalin-related toxicity

Patients should inform their healthcare providers about all medications they are taking to avoid potential drug interactions.

Source: Drugs.com: Pentostalin Drug Interactions

9. Contraindications and Precautions

Pentostalin should not be used in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with renal or hepatic impairment, as dose adjustments may be necessary.

Pentostalin can cause severe myelosuppression (suppression of bone marrow activity), and patients should be monitored closely for signs of infection or bleeding. Appropriate supportive care, including transfusions and antibiotic therapy, may be required.

Source: FDA: Nipent (Pentostatin) Prescribing Information

10. Pharmacokinetics

Pentostalin is administered intravenously and has a relatively short half-life of approximately 6 hours. It is metabolized primarily by the enzyme adenosine deaminase, which it inhibits, and is excreted in the urine as unchanged drug and metabolites.

The bioavailability of Pentostalin after intravenous administration is not known, as it is not administered orally. However, its pharmacokinetic properties may be affected by factors such as renal and hepatic function, as well as potential drug interactions.

Source: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

11. Clinical Trials and Research

Numerous clinical trials have been conducted to evaluate the efficacy and safety of Pentostalin in the treatment of various hematologic malignancies, particularly hairy cell leukemia and T-cell prolymphocytic leukemia.

One key clinical trial, published in the New England Journal of Medicine in 1984, demonstrated a high rate of complete remission in patients with hairy cell leukemia treated with Pentostalin. This study played a significant role in the approval of Pentostalin for the treatment of hairy cell leukemia.

Ongoing research continues to explore the potential use of Pentostalin in combination with other chemotherapeutic agents or as part of novel treatment regimens for various types of leukemia and lymphomas.

Source: New England Journal of Medicine: Treatment of Hairy-Cell Leukemia with 2′-Deoxycoformycin

12. Regulatory Status and Approval

Pentostalin (Nipent®) was approved by the U.S. Food and Drug Administration (FDA) in 1992 for the treatment of hairy cell leukemia in patients who have failed or relapsed after treatment with alpha-interferon.

Pentostalin has also received regulatory approval in various other countries for the treatment of hairy cell leukemia and, in some cases, other hematologic malignancies.

It is important to note that the regulatory status and approved indications for Pentostalin may vary across different countries and regions.

Source: FDA: Nipent (Pentostatin) Approval History

13. Patient Information

Patients receiving Pentostalin should be aware of the potential side effects and follow their healthcare provider’s instructions carefully. They should report any unusual symptoms or adverse reactions to their healthcare provider immediately.

Patients should also inform their healthcare providers about any other medications they are taking, as well as any preexisting medical conditions, to avoid potential drug interactions or contraindications.

It is important for patients to maintain good hydration and follow any dietary recommendations provided by their healthcare team while undergoing treatment with Pentostalin.

Source: Drugs.com: Pentostalin Patient Information

14. Handling and Storage

Pentostalin should be stored at room temperature (20°C to 25°C or 68°F to 77°F) and protected from light. The reconstituted solution should be used immediately or stored at 2°C to 8°C (36°F to 46°F) for no more than 24 hours.

Proper handling precautions should be taken when preparing and administering Pentostalin, as it is a cytotoxic agent. Healthcare professionals should follow appropriate guidelines for the handling and disposal of hazardous drugs.

Source: FDA: Nipent (Pentostatin) Prescribing Information

15. Historical and Future Perspectives

Pentostalin was first synthesized in the 1970s and underwent extensive preclinical and clinical testing before being approved for the treatment of hairy cell leukemia in the early 1990s. Its development marked a significant milestone in the treatment of this rare type of leukemia.

While Pentostalin continues to be a mainstay in the treatment of hairy cell leukemia, ongoing research is exploring its potential use in combination with other agents or in the treatment of other hematologic malignancies. Additionally, efforts are underway to develop new formulations or delivery methods to improve the efficacy and safety of Pentostalin.

As our understanding of cancer biology and targeted therapies advances, Pentostalin may play an important role in the development of novel treatment strategies for various types of leukemia and lymphomas.

Source: PubMed: Pentostatin in the treatment of hairy cell leukemia